
-
Cruise to showcase last 'Mission: Impossible' at Cannes
-
Stocks, oil bounce after tariffs-fuelled rout
-
France detains man after death threat against judge who convicted Le Pen
-
At least 18 dead in Dominican Republic nightclub roof collapse
-
Pentagon chief fires US military representative to NATO
-
Late Harrods owner 'ruined lives' of alleged victims: lawyer
-
Zelensky says Ukraine captured two Chinese nationals fighting for Russia
-
Charles and Camilla mark 20 years of marriage that defied the odds
-
$20 mn blue diamond goes on show in Abu Dhabi
-
'Spectacular' unbeaten Barca not invincible, says Gavi
-
Iran says deal can be reached if US shows goodwill
-
King Charles meets Italian president in pomp-filled state visit
-
France allowed 'major failures' in finances of 2023 Rugby World Cup: watchdog
-
Stocks, oil recover slightly awaiting Trump's next tariffs moves
-
Prince Harry in court to challenge 'unjustified' UK security downgrade
-
Australian PM tells voters he's ready for Trump tariffs
-
Which stars will join De Niro at Cannes this year?
-
UN urged to probe sonic weapon allegedly used on Serbian protesters
-
World's 'exceptional' heat streak lengthens into March
-
S Korea opposition leader frontrunner in snap presidential election
-
Frail David Hockney celebrated in vast Paris retrospective
-
Flypast for King Charles as he meets Italian president
-
'Malignant stupidity', 'weak': Economists on Trump's tariffs
-
MotoGP world champion Martin to make injury return in Qatar
-
Prince Harry in court to challenge UK security downgrade
-
Philippines adds speedy warship to maritime arsenal
-
Prominent US academic detained on Thai royal insult charge
-
Markets stage mild rebound but Trump tariff uncertainty reigns
-
Emotion the key for inconsistent Dortmund against Barcelona
-
Myanmar garment manufacturers warn US tariffs imperil quake recovery
-
Once-dying Mexican river delta slowly nursed back to life
-
NATO chief says China military expansion 'staggering'
-
South Korea sets new presidential election for June 3
-
Indonesia stocks plunge on Trump tariffs after weeklong break
-
Two Nepalis swept away by Annapurna avalanche
-
Vietnam says to buy more US goods as it seeks tariff delay
-
Why is the NBA eyeing Europe?
-
Mexico mourns photographers killed in music festival mishap
-
Nose job boom in Iran where procedure can boost social status
-
Clean streets vs business woes: pollution charge divides Londoners
-
Mexico mourns photographers killed in music festical mishap
-
Asian markets stage mild rebound but Trump tariff uncertainty reigns
-
Spain PM heads to China, Vietnam as US tariff blitz bites
-
Hong Kong firm did not uphold Panama Canal ports contract: Panama audit
-
Prince Harry mounts new court challenge over UK security downgrade
-
South Korea sets presidential election for June 3: acting president
-
France have 'great chance' against New Zealand despite weakened side: ex-All Black Cruden
-
Australia's concussion-blighted Pucovski retires from cricket at 27
-
Global temperatures at near historic highs in March: EU monitor
-
'Major brain drain': Researchers eye exit from Trump's America
NGG | 1.48% | 63.847 | $ | |
SCS | -0.39% | 10.16 | $ | |
RBGPF | -12.83% | 60.27 | $ | |
CMSC | 0.6% | 22.303 | $ | |
RYCEF | -0.98% | 8.15 | $ | |
GSK | 0.23% | 34.92 | $ | |
BCC | 2.45% | 94.195 | $ | |
RIO | 0.34% | 54.745 | $ | |
RELX | 2.69% | 46.79 | $ | |
CMSD | 0.74% | 22.648 | $ | |
VOD | 0.24% | 8.37 | $ | |
BP | 0.96% | 27.434 | $ | |
BTI | 2.05% | 40.255 | $ | |
BCE | -0.91% | 21.88 | $ | |
AZN | 1.44% | 66.75 | $ | |
JRI | 2.62% | 11.563 | $ |

Experts encouraged by Alzheimer drug preliminary data
Experts on Wednesday said they were encouraged after preliminary data for a new Alzheimer's drug showed it slowed cognitive decline, the first medicine to accomplish this goal.
The treatment, called lecanemab, was tested in a clinical trial of nearly 1,800 people, and slowed cognitive decline by 27 percent across an 18-month period, according to early results announced by makers Biogen and Eisai.
"This is the first drug that's been shown to not only remove the build-up of a protein called amyloid in the brain, but to have a small but statistically significant impact on cognitive decline in people with early-stage disease," said Susan Kohlhaas of Alzheimer's UK.
But experts cautioned their comments were tempered by the preliminary nature of the results, which were announced by press release ahead of publication in a peer-reviewed journal, as the companies look to bring the treatment to market as early as January 2023 in the United States.
Biogen previously brought another Alzheimer's drug to market called Aduhelm, but there was significant controversy over the evidence it worked, and its approval led to three high-level resignations in the US Food and Drug Administration.
According to a statement by Biogen and Eisai, in addition to slowing cognitive decline, the new treatment also slowed build-up in the brain of the protein amyloid, which forms sticky plaques and kills brain cells.
Side effects included higher rates of swelling and bleeding in the brain in the group that received the treatment compared to the group that received a placebo.
Both treatment and placebo groups had people of similar characteristics, including a broad range of underlying conditions. A quarter were either Hispanic or African American.
Michel Vounatsos, CEO of Biogen, said the announcement "gives patients and their families hope that lecanemab, if approved, can potentially slow the progression of Alzheimer's disease."
Masud Husain, a professor of neurology at the University of Oxford, said in a statement: "While the summary of the results certainly seems very encouraging, we have to be cautious until we are allowed to review the data fully.
"It is also important to bear in mind that the trial results apply only to people with mild Alzheimer's disease, not everyone with the condition, and that there were important side effects of the drug, including bleeds in the brain."
J.Pereira--PC